KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Finished Goods (2016 - 2024)

Nektar Therapeutics (NKTR) has 13 years of Finished Goods data on record, last reported at $2.2 million in Q2 2024.

  • For Q2 2024, Finished Goods changed N/A year-over-year to $2.2 million; the TTM value through Jun 2024 reached $2.2 million, changed N/A, while the annual FY2023 figure was $1.4 million, 76.86% down from the prior year.
  • Finished Goods reached $2.2 million in Q2 2024 per NKTR's latest filing, down from $4.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $5.9 million in Q4 2022 and bottomed at $921000.0 in Q3 2023.
  • Average Finished Goods over 3 years is $2.9 million, with a median of $2.2 million recorded in 2024.
  • The widest YoY moves for Finished Goods: up 76.86% in 2023, down 76.86% in 2023.
  • A 3-year view of Finished Goods shows it stood at $5.9 million in 2022, then crashed by 76.86% to $1.4 million in 2023, then skyrocketed by 58.53% to $2.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $2.2 million in Q2 2024, $4.3 million in Q1 2024, and $1.4 million in Q4 2023.